{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T01:34:21Z","timestamp":1789263261171,"version":"build-2803163510"},"reference-count":14,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T00:00:00Z","timestamp":1704412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Rituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin\u2019s lymphomas, have been recognized to exceed the effective dose required for inducing B-cell depletion, considering that the B-cell burden in pemphigus vulgaris is considerably lower than in lymphoproliferative disorders. We herein report our experience with very ultra-low-dose rituximab in two patients affected by pemphigus vulgaris.<\/jats:p>","DOI":"10.3390\/antib13010004","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T03:43:00Z","timestamp":1704426180000},"page":"4","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9098-4124","authenticated-orcid":false,"given":"Christian","family":"Ciolfi","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-7649","authenticated-orcid":false,"given":"Jacopo","family":"Tartaglia","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Alaibac","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Malik, A.M., Tupchong, S., Huang, S., Are, A., Hsu, S., and Motaparthi, K. (2021). An Updated Review of Pemphigus Diseases. Medicina, 57.","DOI":"10.3390\/medicina57101080"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/jdv.16752","article-title":"Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)","volume":"34","author":"Joly","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_3","first-page":"e40734","article-title":"Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology","volume":"15","author":"Khandelwal","year":"2023","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.2217\/fon.14.146","article-title":"Rituximab: Modes of action, remaining dispute and future perspective","volume":"10","author":"Abulayha","year":"2014","journal-title":"Future Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1038\/jid.2008.172","article-title":"Rituximab exerts a dual effect in pemphigus vulgaris","volume":"128","author":"Eming","year":"2008","journal-title":"J. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41598-017-17934-6","article-title":"Single, very low rituximab doses in healthy volunteers\u2014A pilot and a randomized trial: Implications for dosing and biosimilarity testing","volume":"8","author":"Schoergenhofer","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.2147\/PPA.S350756","article-title":"Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability","volume":"16","author":"Ciolfi","year":"2022","journal-title":"Patient Prefer. Adherence"},{"key":"ref_8","unstructured":"Genentech (2023, September 11). Rituxan\u00ae (rituximab [Oncology]). Information for Healthcare Providers. Available online: https:\/\/www.gene.com\/medical-professionals\/medicines\/rituxan-oncology."},{"key":"ref_9","unstructured":"EMA MabThera (2023, September 11). European Medicines Agency; 17 September 2018. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mabthera."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: A systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm. Venereol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: A retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/bjd.12972","article-title":"Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: A randomized, comparative, observer-blinded study","volume":"170","author":"Kanwar","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jdv.12080","article-title":"Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities","volume":"28","author":"Cho","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/14712598.2020.1727440","article-title":"Ultra-low dose rituximab for refractory pemghigus vulgaris: A pilot study","volume":"20","author":"Russo","year":"2020","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/1\/4\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:40:19Z","timestamp":1760103619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/1\/4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,5]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["antib13010004"],"URL":"https:\/\/doi.org\/10.3390\/antib13010004","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,5]]}}}